Etatsizin - antiarrhythmic
1C drug class. Most reviews referred to etatsizin high pharmacotherapeutic efficacy and clinical safety of the drug.
Amiokordin, Amiodarone, Asparkam, arrhythmia, Cordarone, Multak, Panangin, Ritmokard, Propanorm, Tiodaron - drugs analogues etatsizin appearing with him in the same pharmacological group.
Structure and Composition
According Etatsizin instructions issued in the form of circular tablets (0, 05 g), and a 2, a 5% solution for injections (ampoules by 2 ml).
The composition of each tablet is included 0, 05 g of phenothiazine hydrochloride karboetoksiaminodietilaminopropionil and auxiliary components (methyl cellulose, potato starch, sucrose, calcium stearate).
Pharmacological action etatsizin
Etatsizin significantly reduces the frequency of sinus rhythm, atrioventricular slow, atrial, sinotrialnuyu and intraventricular conduction. The drug has a mild coronary dilator, antispasmodic, anticholinergic and pronounced antiarrhythmic effect.
Action etatsizin and analogues etatsizin improves the functional state of the heart area with insufficient blood circulation. Etatsizin slows the rising edge of the action potential, sodium channel conductance limiting outer and inner sides of the membrane cardiomyocytes. In addition, the drug inhibits calcium channels, providing moderate vagolytic action. All of this slows down the process of excitation and inhibition contributes to ectopic foci of automaticity in the myocardium of the ventricles and atria.
Within 30-60 minutes after administration Etatsizin found in blood. Maximum plasma concentration is reached after two to three hours. Etatsizin Bioavailability is 40%. The drug is metabolized in the liver and excreted by the kidneys in the form of metabolites. According to the instructions Etatsizin freely passes into breast milk and through the placenta.
According to the instructions, or use etatsizin analogues etatsizin shown in the following diseases:
- Arrythmia (supraventricular and ventricular);
- Paroxysms of atrial flutter and atrial fibrillation;
- Supraventricular and ventricular tachycardia.
Etatsizin - Instructions for use
According to the instructions Etatsizin in the form of tablets to be taken at an initial dose of 50 mg three times a day. If necessary, the dose is increased (controlled electrocardiogram) to 50 mg four times a day (0, 2 g per day) or 0, 1 g three times a day (0, 3 g per day). When reaching effect on the maintenance treatment in individual doses.
Etatsizin administered intravenously at a dose of 0, 25-1 mg / kg. The contents of ampoules of the drug is diluted with isotonic sodium chloride solution. Time intravenous etatsizin is at least five minutes. More effective with less pronounced side effects considered drip.
- Sinotrialnaya blockade;
- Coronary artery disease in the acute form;
- heart failure;
- Cardiogenic shock;
- Atrioventricular block (II-nd and III-rd degree);
- Marked decrease in blood pressure;
- The liver and kidneys;
- Children under the age of eighteen.
Judging by the reviews,
Etatsizin should be used with caution in angle-closure glaucoma, benign prostatic hyperplasia, cardiomegaly, violations of electrolyte balance (hyperkalemia, hypokalemia, hypomagnesemia).
In some reviews to etatsizin it said that the treatment with this drug may cause tinnitus, a little drowsiness, impaired vision and coordination, dizziness, staggering when walking.
Judging by the reviews to etatsizin when using the drug in maximum doses increases the risk of the emergence and development of cardiac side effects - intraventricular, atrioventricular and sinoatrial blockade, proarrhythmic effect, signs of heart failure.
Do not use this etatsizin with other 1C antiarrhythmic drugs (propafenone, allapinin) and Class IA (aymalinu, procainamide, quinidine, disopyramide).
According to the instructions are not recommended etatsizin combined use with MAO inhibitors.
One-time use etatsizin and beta-blockers can help to strengthen the anti-arrhythmic effect.
Conditions and terms
Etatsizin stored in a dry place, protected from sunlight.
Shelf life of vials of 1, 5 years, 2 tablets a year.